BMS and Indian CRO extend drug discovery contract
- BMS and Syngene International, an Indian contract research organization (CRO), have been working together on drug discovery since 2007.
- The collaboration has produced six candidates for further study.
- The new deal will extend the collaboration by five years, with most of the work taking place in the Bicon Bristol-Myers Research Center (BBRC) in Bangalore.
BMS and Syngene have had eight years of collaborative productivity working on capabilities at the preclinical level, as well as ushering candidates through the research pipeline. Working at the BBRC location, the research teams have meticulously developed capabilities ranging from medicinal and process chemistry to biomarkers, drug metabolism and full-scale pharmaceutical development. Syngene's role is expanding to include more services.
"The scope of Syngene's engagement has expanded to encompass a broad range of integrated service offerings across the drug discovery and development continuum," Syngene International Director Peter Bains told Pharmaceutical Business Review. "We remain committed to supporting Bristol-Myers Squibb in their pursuit of developing new and innovative medicines for the future."
- Pharmaceutical Business Review BMS, Syngene extend research collaboration for five years